301267 Huaxia Eye Hospital Group
- 24.08
- +0.41+1.73%
Huaxia Eye Hospital Group News
Huaxia Ophthalmology (301267): Income steadily growing, waiting for further acceleration.
In the 1-3Q24, the company achieved revenue/net profit attributable to the parent company of 3.182/0.421 billion yuan (yoy +2.6%/-24.5%), with revenue/net profit attributable to the parent company of 1.131/0.155 billion yuan in 3Q24.
Huaxia Ophthalmology: Report for the third quarter of 2024
Huaxia Ophthalmology (301267.SZ): net income in the first three quarters was 0.421 billion yuan, a year-on-year decrease of 24.49%.
Great Wisdom News on October 28th: Huaxia Ophthalmology (301267.SZ) released its third quarter report for 2024, with a company's revenue of 3.182 billion yuan for the first three quarters, a year-on-year increase of 2.55%; net income attributable to the company's shareholders was 0.421 billion yuan, a year-on-year decrease of 24.49%; net income attributable to the company's shareholders after deducting non-recurring gains and losses was 0.417 billion yuan, a year-on-year decrease of 27.23%; basic earnings per share were 0.50 yuan.
Huaxia Ophthalmology (301267): Consumer ophthalmology supports steady revenue growth and nationwide chain layout.
The company released its 2024 interim report, with a revenue of 2.051 billion yuan (YoY +2.85%), and a net income attributable to the parent company of 0.265 billion yuan (YoY -25.15%). National chain layout to consolidate scale effects.
Huaxia Eye (301267): Short-term performance under pressure, long-term growth can be expected.
Event: On August 28, the company released its 2024 interim report, achieving revenue of 2.05 billion yuan in the first half of the year, +2.85% YoY, and achieving a net income attributable to shareholders of 0.265 billion yuan, -25.15% YoY.
Huaxia Ophthalmology: Semi-Annual Report 2024
Huaxia Ophthalmology: 2024 Semi-Annual Report Summary
Express News | Huaxia Ophthalmology: The net income in the first half of the year was 0.265 billion yuan, a year-on-year decrease of 25.15%.
Huaxia Ophthalmology (301267.SZ): The net income in the first half of the year was 0.265 billion yuan, a year-on-year decrease of 25.15%.
Hua Xia Ophthalmology (301267.SZ) announced its semi-annual report for 2024, with a revenue of 2.051 billion yuan, a year-on-year increase of 2.85%; a net income of 0.265 billion yuan attributable to shareholders of listed companies, a year-on-year decrease of 25.15%; a net income of 0.271 billion yuan attributable to shareholders of listed companies, after deducting non-recurring gains and losses, a year-on-year decrease of 25.22%; and a basic earnings per share of 0.32 yuan.
Huaxia Ophthalmology (301267.SZ): No products related to AI glasses have been involved yet.
Huaxia Ophthalmology (301267.SZ) stated on the investor interaction platform on August 15 that the company's main business is medical services in ophthalmology, and it has not yet involved products such as AI glasses.
Huaxia Eye Science and Technology (Stock Code: 301267.SZ) has repurchased 0.78% of its shares.
On August 1st, Gelunhui reported that Huaxia Eye Science and Technology (301267.SZ) had repurchased a total of 6,581,440 shares of the company through a stock repurchase securities account using a centralized bidding trading method as of July 31, 2024, accounting for 0.78% of the company's current total share capital. The highest transaction price was 30.93 yuan/share, the lowest transaction price was 19.38 yuan/share, and the total transaction amount was 18.1 million yuan (excluding transaction fees).
Express News | Huaxia Eye Hospital: The equity distribution for 2023 is 10 shares for every 1.1 yuan, with a stock registration day of July 12.
Huaxia Eye (301267.SZ): Cumulative expenditure of 176 million yuan to repurchase 6.3124 million shares.
On July 1st, Gelonghui reported that Huaxia Ophthalmology (301267.SZ) has cumulatively repurchased 6,312,440 shares of the company through a share repurchase special account for centralized auction trading method as of June 30th, 2024, accounting for 0.75% of the company's current total share capital. The highest fill price was 30.93 yuan/share, the lowest fill price was 20.69 yuan/share, and the total fill amount was 175,978,500 yuan (excluding transaction costs).
Express News | Huashia Eye Hospital: The company's actual controller and director have been released from detention and surveillance.
Huaxia Eye Hospital (301267.SZ) has repurchased 0.62% of the shares.
Huaxia Eye Medicine(301267.SZ) announced that by May 31, 2024, it repurchased a total of 5,225,140 shares through the share repurchase securities account in the concentrated bidding trading method, accounting for 0.62% of the company's current total share capital. The highest fill price was 30.93 yuan/share, and the lowest fill price was 25.01 yuan/share. The total accumulated transaction amount was 150,985,900 yuan (excluding transaction fees).
Huaxia Ophthalmology (301267): Steady increase in revenue and profit, and the M&A Juxin-1 epitaxial expansion logic is gradually being implemented
Investment Highlights: Announcement: Huaxia Ophthalmology Releases 2023 Annual Report and 2024 Quarterly Report? Revenue and profit increased steadily. 2023 revenue of 4,013 billion yuan (+24.12%), gross margin 49.0
Huaxia Ophthalmology (301267): Steady growth in performance, acceleration of epitaxial mergers and acquisitions
Description of the incident on April 25, the company released the 2023 annual report and the 2024 quarterly report: the company's revenue in 2023 was 4,013 billion yuan, up 24.12% year on year; net profit to mother was 666 million yuan, the same
Huaxia Ophthalmology (301267): Dominant disciplines lead growth, and the implementation of epitaxial mergers and acquisitions is expected to increase annual performance
Note: On April 25, the company released its 23 annual report and 24 quarterly report. The company's revenue in '23 was 4,013 billion yuan (+24.12%), net profit to mother was 666 million yuan (+29.60%), deducted
Huaxia Ophthalmology (301267): In-vitro hospital integration and implementation continues to improve the national layout
Event: On April 25, 2024, Huaxia Ophthalmology released the 2023 Report and 24Q1 Report. In 2023, the company achieved revenue of 4,013 billion yuan (+24.12%) and net profit of 666 million yuan (+30) to mother
Huaxia Ophthalmology (301267): Performance is in line with expectations, and epitaxial mergers and acquisitions are about to be implemented
Maintain an increase in holdings rating. Considering the recovery in consumer medicine and the pace of implementation of hospital mergers and acquisitions, the 2024-2025 EPS forecast was lowered to 0.94/1.07 yuan (originally 1.14/1.48 yuan), and the forecast for 2026
Analysis
Price Target
No Data
No Data